This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Prasad has played a key role in shaping Dr. Reddy’s into a globally respected organisation
The purpose of this investment is to meet the expenditure relating to the civil works to be undertaken for setting up of a manufacturing facility
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
The inspection was conducted from July 22-25, 2025
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
The company received one observation in the Form-483
Subscribe To Our Newsletter & Stay Updated
